Bolt Biotherapeutics, Inc. (BOLT) stock
BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 11/3031% below fair value
$5.91−0.35 (-5.59%)
Close on Nov 12, 2026Market cap $11.38MP/E –Yield –
Bolt Biotherapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Bolt Biotherapeutics's operating margin for the twelve months ending Jun 30, 2026 was -654.5%. For fiscal 2025 it was -469.3%, against -949.9% the year before. The highest annual figure on record is -469.3% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -469.3% | +480.6 |
| FY2024 | Dec 31, 2024 | -949.9% | +17.5 |
| FY2023 | Dec 31, 2023 | -967.4% | +609.1 |
| FY2022 | Dec 31, 2022 | -1576.6% | +5787.6 |
| FY2021 | Dec 31, 2021 | -7364.1% | +13926.8 |
| FY2020 | Dec 31, 2020 | -21290.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -167480.0% | −166969.5 |
| Q1 FY2026 | Mar 31, 2026 | -29234.6% | −28243.2 |
| Q4 FY2025 | Dec 31, 2025 | -283.4% | +1157.7 |
| Q3 FY2025 | Sep 30, 2025 | -355.1% | +1417.2 |
| Q2 FY2025 | Jun 30, 2025 | -510.5% | −186.5 |
| Q1 FY2025 | Mar 31, 2025 | -991.4% | −45.2 |
| Q3 FY2024 | Sep 30, 2024 | -1441.1% | −721.8 |
| Q2 FY2024 | Jun 30, 2024 | -1772.3% | −388.4 |
| Q1 FY2024 | Mar 31, 2024 | -324.1% | +684.4 |
| Q4 FY2023 | Dec 31, 2023 | -946.2% | +544.9 |
| Q3 FY2023 | Sep 30, 2023 | -719.3% | +338.8 |
| Q2 FY2023 | Jun 30, 2023 | -1383.9% | +271.4 |
| Q1 FY2023 | Mar 31, 2023 | -1008.5% | +1928.3 |
| Q4 FY2022 | Dec 31, 2022 | -1491.1% | +3838.6 |
| Q3 FY2022 | Sep 30, 2022 | -1058.0% | +2070.4 |
| Q2 FY2022 | Jun 30, 2022 | -1655.3% | +14926.7 |
| Q1 FY2022 | Mar 31, 2022 | -2936.8% | +2395.5 |
| Q4 FY2021 | Dec 31, 2021 | -5329.7% | – |
| Q3 FY2021 | Sep 30, 2021 | -3128.5% | – |
| Q2 FY2020 | Jun 30, 2020 | -16582.1% | – |
| Q1 FY2020 | Mar 31, 2020 | -5332.3% | – |
See a number that looks wrong?